doi: 10.1016/S0140-6736(18)32261-X 37 HomePDShamannaPStewartMYangFMillerMPerryCet al
Clinical Results with Combination Therapy The SURPASS-COMBO trial demonstrated remarkable outcomes with CagriSema
Weight and trend One weigh-in in the first month is noise
Exercise preserves muscle loss in caloric deficits Being in a caloric deficit alone can result in 10%-30%, even 40% in some cases, of the weight lost from muscle mass
In the near term, Novo Nordisk expects FDA approval for its semaglutide successor CagriSema (cagrilintide + semaglutide), a GLP-1/amylin combination, in late 2026
Studies have shown that malfunction and mutation of p53 gene may lead to an escalation in cell proliferation and a reduction in apoptosis, ultimately carcinogenesis, including gastric carcinogenesis (Moss, 1998